Passage Bio, Inc.

PASG Healthcare Biotechnology

In the quarter to June 2026, EPS grew 17.6% and free cash flow fell 59.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

3.48 0.12 −3.33%
Market cap
$11.6M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Current Ratio

+8 more quarters

2.51 2.07 1.73 1.22
Net Debt/EBITDA
6.23 3.39 4.11 2.93
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(1.53) (2.04) (4.04) (2.86)
Book value per Share
9.79 5.91 3.67 1.39
Free Cash Flow
(4.85) (6.48) (12.97) (9.18)
Other line items

Show all line items

Columns are period end dates